Yoko Kataoka
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Prevalence, Severity, and Clinical Course of Atopic Dermatitis in Japan: A Web-Based Questionnaire Survey.
Journal: The Journal of dermatology
Published: April 26, 2026
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study.
Journal: Advances in therapy
Published: January 21, 2026
Characterization of Prurigo Nodules in Adults With Moderate-To-Severe Atopic Dermatitis in Japan: A 2-Year Observational Study.
Journal: The Journal of dermatology
Published: September 09, 2025
Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan.
Journal: The Journal of dermatology
Published: May 12, 2025
In Vitro Evidence Demonstrating the Nondepleting Mechanism of Action of Amlitelimab, an OX40 Ligand Monoclonal Antibody.
Journal: Acta dermato-venereologica
Published: April 11, 2025
Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study.
Journal: Allergology international : official journal of the Japanese Society of Allergology
Published: April 09, 2025
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J).
Journal: Current medical research and opinion
Published: December 03, 2024
Questionnaire survey among ophthalmic allergists on dupilumab-associated ocular surface disease in Japan.
Journal: Allergology international : official journal of the Japanese Society of Allergology
Published: September 08, 2024
Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: significance and limitations in the new treatment era.
Journal: Frontiers in allergy
Published: July 31, 2024
Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis.
Journal: The Journal of allergy and clinical immunology
Published: July 26, 2024
Bridging the Gap: Comparing Patient-Clinician Views on Treatment Goals and Communication in the Management of Atopic Dermatitis Within the Asia-Pacific Region.
Journal: Dermatology and therapy
Published: May 27, 2024
Last Updated: 09/26/2026